Theratechnologies Inc., a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients.
Short Term Liabilities: TH's short term assets ($68.8M) exceed its short term liabilities ($27.4M).
Long Term Liabilities: TH's short term assets ($68.8M) exceed its long term liabilities ($50.6M).
Debt to Equity History and Analysis
Debt Level: TH's debt to equity ratio (167.7%) is considered high.
Reducing Debt: Insufficient data to determine if TH's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Inventory Level: TH has a low level of unsold assets or inventory.
Debt Coverage by Assets: TH's debt is covered by short term assets (assets are 1.4x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TH has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if TH has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Theratechnologies's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate TH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate TH's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TH's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TH's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
What is the CEO of Theratechnologies's salary, the management and board of directors tenure and is there insider trading?
3.4yrs
Average management tenure
CEO
LucTanguay(61yo)
7.2yrs
Tenure
US$1,169,180
Compensation
Mr. Luc Tanguay, M.Sc., C.F.A. has been the Chief Executive Officer and President of Theratechnologies Inc. since October 11, 2012. Mr. Tanguay has been active in the biotechnology industry for over 20 yea ...
CEO Compensation Analysis
Compensation vs Market: Luc's total compensation ($USD886.76K) is about average for companies of similar size in the Canadian market ($USD682.76K).
Compensation vs Earnings: Luc's compensation has been consistent with company performance over the past year.
Management Age and Tenure
3.4yrs
Average Tenure
52.5yo
Average Age
Experienced Management: TH's management team is considered experienced (3.4 years average tenure).
Board Age and Tenure
13.8yrs
Average Tenure
66yo
Average Age
Experienced Board: TH's board of directors are seasoned and experienced ( 13.8 years average tenure).
Insider Trading
Insider Buying: TH insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
BuyUS$15,07915 Nov 19
Gary Littlejohn
Entity
Individual
Role
Member of the Board of Directors
Independent Director
Shares
3,190
Max Price
US$4.74
BuyUS$4,85015 Oct 19
Philippe Dubuc
Entity
Individual
Role
Chief Financial Officer
Senior VP & CFO
Shares
1,000
Max Price
US$4.85
BuyUS$19,90330 Apr 19
Philippe Dubuc
Entity
Individual
Role
Chief Financial Officer
Senior VP & CFO
Shares
3,000
Max Price
US$6.66
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Management Team
Luc Tanguay (61yo)
President
Tenure: 7.2yrs
Compensation: US$1.17m
Jocelyn Lafond (51yo)
VP of Legal Affairs & Corporate Secretary
Tenure: 0yrs
Compensation: US$444.16k
Christian Marsolais (56yo)
Senior VP & Chief Medical Officer
Tenure: 3.4yrs
Compensation: US$582.29k
Philippe Dubuc (52yo)
Senior VP & CFO
Tenure: 3.8yrs
Compensation: US$596.33k
Denis Boucher (53yo)
Vice President of Communications & Corporate Affairs
Tenure: 1.9yrs
Compensation: US$457.30k
Jovan Antunovic (49yo)
Senior VP & Chief Commercial Officer
Tenure: 1yrs
Board Members
Roger Guillemin
Member of the Scientific Advisory Board
Tenure: 0yrs
Luc Tanguay (61yo)
President
Tenure: 7.2yrs
Compensation: US$1.17m
Gary Littlejohn (64yo)
Independent Director
Tenure: 1.2yrs
Compensation: US$8.00k
George Merriam
Member of the Scientific Advisory Board
Tenure: 0yrs
David Clemmons
Member of the Scientific Advisory Board
Tenure: 0yrs
Paul Pommier (77yo)
Independent Director
Tenure: 22.9yrs
Compensation: US$109.67k
Gérald Lacoste (75yo)
Independent Director
Tenure: 13.8yrs
Compensation: US$107.50k
Graham Svoronos (66yo)
Chair of the Board
Tenure: 6.6yrs
Compensation: US$208.00k
Steven Grinspoon
Member of the Scientific Advisory Board
Tenure: 0yrs
Peter Reiss
Member of the Scientific Advisory Board
Tenure: 0yrs
Company Information
Theratechnologies Inc.'s company bio, employee growth, exchange listings and data sources
Theratechnologies Inc., a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. It offers EGRIFTA, for the reduction of e ...
Company Analysis and Financial Data Status
All financial data provided by Standard & Poor's Capital IQ.
Data
Last Updated (UTC time)
Company Analysis
2019/12/12 23:48
End of Day Share Price
2019/12/12 00:00
Earnings
2019/08/31
Annual Earnings
2018/11/30
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.